August 28, 2019
A slew of new medicines will be added to Japan’s NHI price list on September 4, with a key reimbursement policy panel giving them the thumbs-up on August 28 including Roche/Chugai Pharmaceutical’s tumor-agnostic agent Rozlytrek (entrectinib) and Alnylam Pharmaceuticals’ Onpattro...read more